Toxicological Research

  • 제21권3호
  • /
  • Pages.241-247
  • /
  • 2005
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지

Antigenicity of HM10760 in Guinea Pigs

  • 발행 : 2005.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

HM10760 is a recombinant human erythropoietin that has beer developed as a drug for anemia. In this study, antigenic potential of HM10760 was examined by active systemic anaphylaxis in guinea pigs and passive cutaneous anaphylaxis in a guinea pig-guinea pig system. HM10760 was subcutaneously administered at 0, 2, and $20{\mu}g/kg$ and also as a suspension with adjuvant ($20{\mu}g/kg$ + FCA). Ovalbumin as a suspension with adjuvant was administered to induce positive control responses. In the active systemic anaphylaxis test, no symptoms except rubbing or licking nose and urination that were considered as physiological phenomena were observed at $0{\mu}g/kg$. Four of 5 animals at $2{\mu}g/kg$ and all the 5 animals at $20{\mu}g/kg$ showed cyanosis and lying on side. All animals in the adjuvant mixture group showed relatively mild symptoms such as rubbing or licking nose, urination, and evacuation. In the passive cutaneous anaphylaxis test, 0/5, 3/5, and 5/5 serum samples from the animals immunized with 0, 2, and $20{\mu}g/kg$, respectively, showed positive reactions against HM10760. All 5 sera collected from the animals immunized with an adjuvant mixture contained HM10760-specific antibodies. These results suggest HM10760 have antigenicity in guinea pigs.

키워드

참고문헌

  1. Bitonti, A.J., Dumont, .J.A., Low, S.C., Peters, R.T., Kropp, K.E., Palombella, V.J. Stattel, J.M., Lu, Y, Tan, C.A., Song, J.J., Garcia, A.M., Simister, N.E., Spiekermann, G.M., Lencer, W.I. and Blumberg, R.S. (2004): Pulmonary delivery of an erythropoietin Fc fusion protein in nonhuman primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA, 101, 9763-9768 https://doi.org/10.1073/pnas.0403235101
  2. Cooper, J.C., Morgan, G, Harding, S., Subramanyam, M., Majeau, G.R, Moulder, K. and Alexander, D.R. (2003): Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J. Immunol., 33, 666-675 https://doi.org/10.1002/eji.200323586
  3. Eschbach, J.W, Egrie, J.C., Downing, M.R., Browne, J.K and Adamson, J.W. (1987): Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med., 316, 73-78 https://doi.org/10.1056/NEJM198701083160203
  4. Gershon, S.K., Luksenburg, H., Cote, T.R. and Braun, M.M. (2002): Pure red cell aplasia and recombinant erythropoietin. N. Engl. J. Med., 346,1584-1586 https://doi.org/10.1056/NEJM200205163462015
  5. Glodberg, M.A. and Schneider, T.J. (1994): Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. BioI. Chem., 269, 4355-4359
  6. Goldwasser, E., Kung, C.K. and Eliason, J. (1974): On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J. Biol. Chem., 249, 4202-4206
  7. Kang, K.K., Cho, H., Baik, N.G. and Kim W.B. (1998): Antigenicity study of recombinant human erythropoietin. J. Appl. Pharmacol., 6, 50-55
  8. Karol, M.H. and Graham, C. (1997): Antibody-mediated hypersensitivity. in [Comprehensive toxicology; Ed. Lawrence D.A., vol. 5 (Toxicology of the immune system)], Pergamon Press, New York, pp. 305-322.
  9. Macdougall, I.C. (2005): Antibody-mediated pure cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol. Dial. Transplant., 20, iv9-15 https://doi.org/10.1093/ndt/gfh1087
  10. Morell, A.G, Irvine, R.A, Sternlieb, I., Scheinberg, I.H. and Ashwell, G (1968): Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J. BioI. Chem., 243, 155-159
  11. Mota, I. and Wong, D. (1969): Homologous and heterologous passive cutaneous anaphylatic activity of mouse antisera during the course of immunization. Life. Sci., 8, 813-820 https://doi.org/10.1016/0024-3205(69)90099-X
  12. Osterborg, A. (2004): New erythropoietic proteins: rationale and clinical data. Semin. Oncol., 3, 12-18 https://doi.org/10.1053/j.seminoncol.2004.04.005
  13. Saito, T., Urabe, A. and Takaku, F. (1984): in vitro assay of erythropoietin: simple determination in a small amount of human serum samples. Jpn. J. Med., 23, 16-21 https://doi.org/10.2169/internalmedicine1962.23.16
  14. Sytkowski, A.J., Lunn, E.D., Risinger, MA and Davis, K.L. (1999): An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological prop- erties. J. Bioi. Chem., 274, 24773-24778 https://doi.org/10.1074/jbc.274.35.24773
  15. Wallner, S.F., Kurnick, J.E., Vautrin, R.M., White, M.J., Chapman, R.G. and Ward, H.P. (1977): Levels of erythropoietin in patients with the anemias of chronic diseases and liver failure. Am. J. Hematol., 3, 37-44 https://doi.org/10.1002/ajh.2830030105
  16. Way, J.C., Lauder, S., Brunkhorst, B., Kong, S.M., Qi, A., Webster, G., Campbell, I., McKenzie, S., Lan, Y., Marelli, B., Nguyen, L.A., Degon, S., Lo, K.M. and Gillies, S.D. (2005): Improvement of Fe-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel., 18, 111-118 https://doi.org/10.1093/protein/gzi021